Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

ABSTRACT: Cardiovascular disease (CVD) is the leading cause of death worldwide. In addition to the high mortality rate, people suffering from CVD often endure difficulties with physical activities and productivity that significantly affect their quality of life. The high prevalence of debilitating risk factors such as obesity, type 2 diabetes mellitus, smoking, hypertension, and hyperlipidemia only predicts a bleak future. Current traditional CVD interventions offer temporary respite; however, they compound the severe economic strain of health-related expenditures. Furthermore, these therapeutics can be prescribed indefinitely. Recent advances in the field of epigenetics have generated new treatment options by confronting CVD at an epigenetic level. This involves modulating gene expression by alteri

SUBMITTER: Gladwell LR 

PROVIDER: S-EPMC10820772 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature